Kenneth H. Shain

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma”.

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Oncotarget(2016)10.18632/oncotarget.12969

N/A

0.680DataRank · unranked

92 citations

Trinayan Kashyap, Jana L. Dawson, Juan Gomez, Alexis A. Bauer, Steven Grant +6 more

A pharmacodynamic model of clinical synergy in multiple myeloma

EBioMedicine(2020)10.1016/j.ebiom.2020.102716

N/A

0.529DataRank · unranked

33 citations

Maria Cláudia Silva, Rafael Renatino Canevarolo, Raghunandan Reddy Alugubelli, Gabriel DeAvila, Alexandre Tungesvik +8 more

Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.7503

N/A

0.360DataRank · unranked

10 citations

Jing Christine Ye, Jens Hillengaß, Douglas W. Sborov, James E. Hoffman, Benjamin Diamond +15 more

Genome-level selection in tumors as a universal marker of resistance to therapy

Nature Communications(2025)10.1038/s41467-025-61709-x

N/A

0.208DataRank · unranked

3 citations

Praneeth Sudalagunta, Yuri I. Wolf, Rafael Renatino Canevarolo, Mehdi Damaghi, Kenneth H. Shain +3 more

Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma

Research Square(2025)10.21203/rs.3.rs-6306816/v1

N/A

0.104DataRank · unranked

1 citations

Rafael Renatino Canevarolo, Praneeth Sudalagunta, Mark B. Meads, Maria João Silva, Xiaohong Zhao +29 more

Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma

Cancer Cell(2025)10.1016/j.ccell.2025.09.007

N/A

0DataRank · unranked

4 citations

Francesca Albano, Annamaria Cesarano, Yunfei Wang, Brandon Kale, Kenneth H. Shain +19 more

Data from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma

(2023)10.1158/0008-5472.c.6500067.v1

N/A

0DataRank · unranked

0 citations

Vasco Oliveira, Linda Mathews, Xingyu Wang, Alejandro Villagra, David R. Boulware +7 more